877624-40-3

Basic information

• Product Name: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE
• Synonyms: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE;3-Bromo-5-bromomethyl-benzoic acid methyl ester
• CAS NO: 877624-40-3
• Molecular Formula: C₉H₈Br₂O₂
• Molecular Weight: 307.98
• Mol File: 877624-40-3.mol

Chemical Properties

• Boiling Point: 344.6±32.0 °C(Predicted)
• Appearance: /
• Density: 1.780±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE(877624-40-3)
• EPA Substance Registry System: METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE(877624-40-3)

Safety Data

• Hazardous Substances Data: 877624-40-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE is utilized for the production of various agrochemical compounds. Its properties contribute to the development of effective solutions for crop protection and pest management.
Used in Organic Synthesis:
METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE is employed as a versatile building block in the synthesis of organic molecules. Its reactivity and functional groups enable the formation of a wide range of chemical compounds for various applications.
Used in Chemical Research and Development:
In the field of chemical research and development, METHYL 3-BROMO-5-(BROMOMETHYL)BENZOATE is used for exploring new chemical reactions and developing innovative synthetic methods. Its unique properties make it an essential tool for advancing scientific knowledge and discovering novel applications.

Upstream product

• 307353-32-8 3-bromo-5-hydroxymethylbenzoic acid methyl ester 
• 58530-13-5 3-bromo-5-methyl-benzoic acid 
• 478375-40-5 methyl 3-bromo-5-methylbenzoate 

Downstream Products

• 954124-68-6 3-bromo-5-(((1-(tert-butoxycarbonyl)-4-phenylpiperidin-4-yl)methoxy)methyl)benzoic acid 
• 878741-84-5 methyl 3-bromo-5-(cyanomethyl)benzoate 

Relevant articles and documents

Identification and structure–activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

Our previously reported carboxyl-containing DPP-4 inhibitors were highly potent but were poorly bioavailable. Esters of the carboxyl analogs exhibited a significant DPP-4 potency loss albeit with enhanced oral absorption. Herein, we described identificati

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. Formula (IIa), (IIb), (IIc)

ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same

Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.

BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME

The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.